A recent prostate cancer study examined the outcomes of CyberKnife® treatment for low and immediate risk patients with early stage prostate cancer. Researchers examined the cases of 32 patients over a two-year period. After receiving CyberKnife treatment, patients experienced lower toxicity levels and fewer instances of recurrence for years following treatment.
Columbus CyberKnife treats prostate cancer patients with stereotactic body radiation therapy (SBRT) using CyberKnife technology. For early stage prostate cancer patients, this treatment method offers unique benefits that allow patients to receive treatment with minimal disruption to their daily activities.
The CyberKnife pinpoints tumors with sub-millimeter accuracy and minimizes radiation exposure to surrounding healthy tissue. CyberKnife’s advanced range of motion allows physicians to treat difficult-to-reach areas in the body. Most patients experience few to no side effects and return to their normal activities immediately following each session.
Read more about the CyberKnife study here or contact Columbus CyberKnife at (614) 898-8300 to learn about the CyberKnife treatment process for prostate cancer and whether you may be a candidate for treatment.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.